ISIS Pharmaceuticals, Inc.  

(Public, NASDAQ:ISIS)   Watch this stock  
Find more results for ISIS
31.65
+0.03 (0.09%)
Real-time:   11:19AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 31.40 - 32.47
52 week 22.25 - 62.66
Open 31.91
Vol / Avg. 397,038.00/2.02M
Mkt cap 3.72B
P/E     -
Div/yield     -
EPS -0.78
Shares 117.58M
Beta 1.27
Inst. own 90%
Aug 4, 2014
Q2 2014 Isis Pharmaceuticals Inc Earnings Call - 10:30AM EDT - Add to calendar
Aug 4, 2014
Q2 2014 Isis Pharmaceuticals Inc Earnings Release - 9:30AM EDT - Add to calendar
Jun 17, 2014
Isis Pharmaceuticals at Wells Fargo Healthcare Conference - Webcast
Jun 16, 2014
Isis Pharmaceuticals to Host Investor Event to Discuss Data Presented at 2014 ADA Scientific Sessions - Webcast
Jun 15, 2014
Isis Pharmaceuticals Analyst Meeting
Jun 11, 2014
Isis Pharmaceuticals at Goldman Sachs Healthcare Conference - Webcast
Jun 10, 2014
Isis' Annual Stockholder Meeting
May 22, 2014
Isis Pharmaceuticals, Inc. R&D Day
May 21, 2014
Isis Pharmaceuticals at UBS Global Healthcare Conference - Webcast
May 7, 2014
Isis Pharmaceuticals, Inc. at Deutsche Bank Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -111.08% -41.17%
Operating margin -105.35% -35.08%
EBITD margin - -28.44%
Return on average assets -14.92% -8.71%
Return on average equity -33.35% -21.61%
Employees 304 -
CDP Score - -

Address

2855 Gazelle Court
CARLSBAD, CA 92010
United States - Map
+1-760-9319200 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Isis Pharmaceuticals, Inc. develops therapeutic drugs inhibiting cell protein synthesis. The Company's principal activity is to develop and market RNA(RiboNucleicAcid)-based novel drugs to treat important diseases such as cardiovascular diseases, diabetes and asthma

Officers and directors

Stanley T. Crooke M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Elizabeth L. Hougen Chief Financial Officer, Senior Vice President - Finance
Age: 52
Bio & Compensation  - Reuters
B. Lynne Parshall J.D. Chief Operating Officer, Corporate Secretary, Director
Age: 59
Bio & Compensation  - Reuters
Patrick R. O'Neil Esq. Senior Vice President - Legal, General Counsel
Age: 40
Bio & Compensation  - Reuters
C. Frank Bennett Ph.D. Senior Vice President - Antisense Research
Age: 57
Bio & Compensation  - Reuters
Richard S. Geary Ph.D. Senior Vice President - Development
Age: 56
Bio & Compensation  - Reuters
Brett P. Monia Ph.D. Senior Vice President - Drug Discovery and Corporate Development
Age: 52
Bio & Compensation  - Reuters
Joseph Loscalzo M.D., Ph.D. Director
Age: 62
Bio & Compensation  - Reuters
Spencer R. Berthelsen M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Breaux B. Castleman Independent Director
Age: 73
Bio & Compensation  - Reuters